Roquefort Therapeutics
Industry: BIOTECHNOLOGY
ROQUEFORT THERAPEUTICS PLC (LSE: ROQ) is a public company listed on the Main Market of the London stock exchange. Roquefort is a biotechnology company developing innovative cancer medicines in the high growth oncology market. Led by CEO AJAN REGINALD, Roquefort has portfolio of four pre-clinical anti-cancer drugs and 46 registered patents.
Ajan Reginald: Biotech Entrepreneur
Roquefort Therapeutics (LSE: ROQ, QTCQB: ROQAF) (Roquefort) is an LSE main-market-listed BioTech company exploring the high-value and high-growth oncology market. We at Colitco secured an
Roquefort Therapeutics PLC (LSE: ROQ) and Randox Laboratories Strike Exclusive License Agreement for Medical Diagnostics
Roquefort Therapeutics PLC (LSE: ROQ, OTCQB: ROQAF), a cancer-focused biotechnology company, has made a significant announcement recently. The Company has signed an exclusive licensing and
Roquefort Therapeutics Reports In-Vivo Safety for Midkine Oncology Antibodies
Roquefort Therapeutics (LSE: ROQ, OTCQB: ROQAF) (“Roquefort” or the “Company”) announces that two of its Midkine (MDK) antibody programs, ROQ-A1 and ROQ-A2, demonstrate in-vivo safety in
Roquefort Therapeutics and CEO Ajan Reginald: An Inspiring Story
Roquefort Therapeutics PLC (LSE: ROQ) (Roquefort or the “Company”) is a public company listed on the Main Market of the London stock exchange. Roquefort is